Literature DB >> 34859485

Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.

Whitney K Hendrickson1, Gongbo Xie2, David D Rahn3, Cindy L Amundsen1, James A Hokanson4, Megan Bradley5, Ariana L Smith6, Vivian W Sung7, Anthony G Visco1, Sheng Luo2, J Eric Jelovsek1.   

Abstract

AIMS: Develop models to predict outcomes after intradetrusor injection of 100 or 200 units of onabotulinumtoxinA in women with non-neurogenic urgency urinary incontinence (UUI).
METHODS: Models were developed using 307 women from two randomized trials assessing efficacy of onabotulinumtoxinA for non-neurogenic UUI. Cox, linear and logistic regression models were fit using: (1) time to recurrence over 12 months, (2) change from baseline daily UUI episodes (UUIE) at 6 months, and (3) need for self-catheterization over 6 months. Model discrimination of Cox and logistic regression models was calculated using c-index. Mean absolute error determined accuracy of the linear model. Calibration was demonstrated using calibration curves. All models were internally validated using bootstrapping.
RESULTS: Median time to recurrence was 6 (interquartile range [IQR]: 2-12) months. Increasing age, 200 units of onabotulinumtoxinA, higher body mass index (BMI) and baseline UUIE were associated with decreased time to recurrence. The c-index was 0.63 (95% confidence interval [CI]: 0.59, 0.67). Median change in daily UUIE from baseline at 6 months was -3.5 (IQR: -5.0, -2.3). Increasing age, lower baseline UUIE, 200 units of onabotulinumtoxinA, higher BMI and IIQ-SF were associated with less improvement in UUIE. The mean absolute error predicting change in UUIE was accurate to 1.6 (95% CI: 1.5, 1.7) UUI episodes. The overall rate of self-catheterization was 17.6% (95% CI: 13.6%-22.4%). Lower BMI, 200 units of onabotulinumtoxinA, increased baseline postvoid residual and maximum capacity were associated with higher risk of self-catheterization. The c-index was 0.66 (95% CI: 0.61, 0.76). The three calculators are available at http://riskcalc.duke.edu.
CONCLUSIONS: After external validation, these models will assist clinicians in providing more accurate estimates of expected treatment outcomes after onabotulinumtoxinA for non-neurogenic UUI in women.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  ABC; BoNT-A; ROSETTA; UUI; botox; prediction model; urgency urinary incontinence

Mesh:

Substances:

Year:  2021        PMID: 34859485      PMCID: PMC9014828          DOI: 10.1002/nau.24845

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.367


  43 in total

1.  Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.

Authors:  Daniel Liberman; Olufenwa Milhouse; Marta Johnson-Mitchell; Steven W Siegel
Journal:  Female Pelvic Med Reconstr Surg       Date:  2018 Nov/Dec       Impact factor: 2.091

2.  A model for predicting the risk of de novo stress urinary incontinence in women undergoing pelvic organ prolapse surgery.

Authors:  J Eric Jelovsek; Kevin Chagin; Linda Brubaker; Rebecca G Rogers; Holly E Richter; Lily Arya; Matthew D Barber; Jonathan P Shepherd; Tracy L Nolen; Peggy Norton; Vivian Sung; Shawn Menefee; Nazema Siddiqui; Susan F Meikle; Michael W Kattan
Journal:  Obstet Gynecol       Date:  2014-02       Impact factor: 7.661

3.  Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.

Authors:  Yuko M Komesu; Cindy L Amundsen; Holly E Richter; Stephen W Erickson; Mary F Ackenbom; Uduak U Andy; Vivian W Sung; Michael Albo; W Thomas Gregory; Marie Fidela Paraiso; Dennis Wallace
Journal:  Am J Obstet Gynecol       Date:  2017-10-12       Impact factor: 8.661

4.  Multiple imputation using chained equations: Issues and guidance for practice.

Authors:  Ian R White; Patrick Royston; Angela M Wood
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

5.  Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela R Paraiso; Shawn A Menefee; Joseph Schaffer; Jerry Lowder; Salil Khandwala; Larry Sirls; Cathie Spino; Tracy L Nolen; Dennis Wallace; Susan F Meikle
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

Review 6.  Treatment of overactive bladder in women.

Authors:  Katherine E Hartmann; Melissa L McPheeters; Danie H Biller; Renée M Ward; J Nikki McKoy; Rebecca N Jerome; Sandra R Micucci; Laura Meints; Jill A Fisher; Theresa A Scott; James C Slaughter; Jeffrey D Blume
Journal:  Evid Rep Technol Assess (Full Rep)       Date:  2009-08

7.  Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019.

Authors:  Deborah J Lightner; Alexander Gomelsky; Lesley Souter; Sandip P Vasavada
Journal:  J Urol       Date:  2019-08-08       Impact factor: 7.450

8.  Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement.

Authors:  Gary S Collins; Johannes B Reitsma; Douglas G Altman; Karel G M Moons
Journal:  Ann Intern Med       Date:  2015-01-06       Impact factor: 25.391

9.  Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder.

Authors:  Qin-Qin Gong; Yu-Qiong Xu; Jun Xu; Xiao-Yan Ding; Chong Guo
Journal:  Front Pharmacol       Date:  2020-01-15       Impact factor: 5.810

10.  A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages.

Authors:  Hui-Yun Gu; Ju-Kun Song; Wen-Jun Zhang; Jin Xie; Qi-Sheng Yao; Wen-Jing Zeng; Chao Zhang; Yu-Ming Niu
Journal:  Oncotarget       Date:  2017-08-07
View more
  2 in total

Review 1.  Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?

Authors:  Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2022-07-18       Impact factor: 5.075

Review 2.  Delivering patient-centered care through shared decision making in overactive bladder.

Authors:  Roshan Paudel; Giulia I Lane
Journal:  Neurourol Urodyn       Date:  2022-03-25       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.